Related content

Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers

By Svane Inge   Pedersen Anders   Johansen Julia   Johnsen Hans   Nielsen Dorte   Kamby Claus   Ottesen Svend   Balslev Eva   Gaarsdal Eva   Nikolajsen Kirsten   Claesson Mogens  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 9, 2007-09 ,pp. : 1485-1499

Springer Publishing Company

Access to resources Recommend Favorite

Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide–pulsed dendritic cells

By Matsuda Kenji   Tsunoda Takuya   Tanaka Hajime   Umano Yasukazu   Tanimura Hiroshi   Nukaya Ikuei   Takesako Kazutoh   Yamaue Hiroki  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 609-616

Springer Publishing Company

Access to resources Recommend Favorite

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34⁺ progenitor-derived dendritic cells

By Fay Joseph   Palucka A.   Paczesny Sophie   Dhodapkar Madhav   Johnston Dennis   Burkeholder Susan   Ueno Hideki   Banchereau Jacques  

Cancer Immunology, Immunotherapy, Vol. 55, Iss. 10, 2006-10 ,pp. : 1209-1218

Springer Publishing Company

Access to resources Recommend Favorite

High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer

By Met Özcan   Balslev Eva   Flyger Henrik   Svane Inge  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 395-406

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

By                  

International Journal of Oncology, Vol. 44, Iss. 3, 2014-01 ,pp. : 662-668

Spandidos Publications

Access to resources Recommend Favorite